Although EPM301 is not a peripherally restricted compound, psychiatric side effects, which were observed with the global CB1R antagonist rimonabant, are not expected with EPM301 due to its reported beneficial effects in reducing anxiety and depression [28,29], as well as its probable inability to block the CB1R (although this was not tested here). The gene discussed is CNR1; the disease is depressive disorder.